2335299
Project Grant
Overview
Grant Description
Sttr Phase I: Injectable Biotherapeutic for Treatment of Post-Traumatic Osteoarthritis -This small business technology transfer (STTR) Phase I project develops an injectable therapeutic to treat post-traumatic osteoarthritis (PTOA). PTOA is a painful disease of the cartilage caused by external mechanical force.
The current treatment for PTOA involves an invasive surgical procedure - total joint replacement - which is often associated with infections and may need a revision knee replacement. There is no disease-modifying osteoarthritis drug nor a non-surgical cure for these patients.
While some drugs help mitigate pain, they have no effect on disease progression, and their use can be limited greatly by their potential severe side effects. This solution serves as the first and only treatment to slow the progression of PTOA, which would prevent PTOA patients from potentially suffering a lifetime of pain and expenses.
As a result, customers will potentially save thousands of dollars, acquire peace of mind that they have taken the only action to help prevent the development of osteoarthritis, and most of all, prevent a cycle of increasing pain, medical issues, and associated treatments with their injury. This small business technology transfer (STTR) Phase I project will lead to an optimized, deimmunized therapeutic that changes the disease progression of post-traumatic osteoarthritis (PTOA).
The solution combines a unique thermoresponsive hydrogel carrier capable of sustained delivery of a therapeutic protein that enables disease modification when delivered via a single injection, avoiding the surgical procedure in total joint replacement. State-of-the-art computational tools will be employed to improve the properties of the hydrogel and experimentally test the constructs for function.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.- Subawards are planned for this award.
The current treatment for PTOA involves an invasive surgical procedure - total joint replacement - which is often associated with infections and may need a revision knee replacement. There is no disease-modifying osteoarthritis drug nor a non-surgical cure for these patients.
While some drugs help mitigate pain, they have no effect on disease progression, and their use can be limited greatly by their potential severe side effects. This solution serves as the first and only treatment to slow the progression of PTOA, which would prevent PTOA patients from potentially suffering a lifetime of pain and expenses.
As a result, customers will potentially save thousands of dollars, acquire peace of mind that they have taken the only action to help prevent the development of osteoarthritis, and most of all, prevent a cycle of increasing pain, medical issues, and associated treatments with their injury. This small business technology transfer (STTR) Phase I project will lead to an optimized, deimmunized therapeutic that changes the disease progression of post-traumatic osteoarthritis (PTOA).
The solution combines a unique thermoresponsive hydrogel carrier capable of sustained delivery of a therapeutic protein that enables disease modification when delivered via a single injection, avoiding the surgical procedure in total joint replacement. State-of-the-art computational tools will be employed to improve the properties of the hydrogel and experimentally test the constructs for function.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.- Subawards are planned for this award.
Awardee
Funding Goals
THE GOAL OF THIS FUNDING OPPORTUNITY, "NSF SMALL BUSINESS INNOVATION RESEARCH (SBIR)/ SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAMS PHASE I", IS IDENTIFIED IN THE LINK: HTTPS://WWW.NSF.GOV/PUBLICATIONS/PUB_SUMM.JSP?ODS_KEY=NSF23515
Grant Program (CFDA)
Awarding Agency
Place of Performance
New York,
New York
10003-5245
United States
Geographic Scope
Single Zip Code
Related Opportunity
Analysis Notes
Amendment Since initial award the total obligations have increased 7% from $275,000 to $295,000.
Provizigen was awarded
Project Grant 2335299
worth $295,000
from in November 2023 with work to be completed primarily in New York New York United States.
The grant
has a duration of 1 year and
was awarded through assistance program 47.084 NSF Technology, Innovation, and Partnerships.
The Project Grant was awarded through grant opportunity NSF Small Business Innovation Research / Small Business Technology Transfer Phase I Programs.
SBIR Details
Research Type
STTR Phase I
Title
STTR Phase I: Injectable Biotherapeutic for Treatment of Post-Traumatic Osteoarthritis
Abstract
This Small Business Technology Transfer (STTR) Phase I project develops an injectable therapeutic to treat post-traumatic osteoarthritis (PTOA). PTOA is a painful disease of the cartilage caused by external mechanical force. The current treatment for PTOA involves an invasive surgical procedure - total joint replacement - which is often associated with infections and may need a revision knee replacement. There is no disease-modifying osteoarthritis drug nor a non-surgical cure for these patients. While some drugs help mitigate pain, they have no effect on disease progression, and their use can be limited greatly by their potential severe side effects. This solution serves as the first and only treatment to slow the progression of PTOA, which would prevent PTOA patients from potentially suffering a lifetime of pain and expenses. As a result, customers will potentially save thousands of dollars, acquire peace of mind that they have taken the only action to help prevent the development of osteoarthritis, and most of all, prevent a cycle of increasing pain, medical issues, and associated treatments with their injury.
This Small Business Technology Transfer (STTR) Phase I project will lead to an optimized, deimmunized therapeutic that changes the disease progression of post-traumatic osteoarthritis (PTOA). The solution combines a unique thermoresponsive hydrogel carrier capable of sustained delivery of a therapeutic protein that enables disease modification when delivered via a single injection, avoiding the surgical procedure in total joint replacement. State-of-the-art computational tools will be employed to improve the properties of the hydrogel and experimentally test the constructs for function.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Topic Code
BM
Solicitation Number
NSF 23-515
Status
(Complete)
Last Modified 9/17/24
Period of Performance
11/1/23
Start Date
10/31/24
End Date
Funding Split
$295.0K
Federal Obligation
$0.0
Non-Federal Obligation
$295.0K
Total Obligated
Activity Timeline
Transaction History
Modifications to 2335299
Additional Detail
Award ID FAIN
2335299
SAI Number
None
Award ID URI
SAI EXEMPT
Awardee Classifications
Small Business
Awarding Office
491503 TRANSLATIONAL IMPACTS
Funding Office
491503 TRANSLATIONAL IMPACTS
Awardee UEI
KT8KEDVPJJZ8
Awardee CAGE
9GB58
Performance District
NY-12
Senators
Kirsten Gillibrand
Charles Schumer
Charles Schumer
Modified: 9/17/24